ORYZON Receives a New 0.8 M USD Public Grant to Explore New Indications for Epigenetic Inhibitors
BARCELONA, SPAIN and CAMBRIDGE MA.
• Within a consortium, led by Oryzon, that will have a 1.3M USD aggregated budget
Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the Company will receive a new grant in the form of a loan with interest rate granted, from the Ministry of Economy and Competitiveness, Government of Spain and FEDER Funds from the European Union and included under the RETOS Collaboration 2016 program. Oryzon will receive approximately 0.8M USD (multiyear disbursements) for further development of its epigenetic inhibitors against inflammatory indications.